Literature DB >> 8864905

Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration.

G Boivin1, P Deloffre, B Perrat, G Panczer, M Boudeulle, Y Mauras, P Allain, Y Tsouderos, P J Meunier.   

Abstract

The analysis of the interaction of strontium (Sr) with bone mineral is of interest because a new agent containing Sr (S 12911) has shown positive effects on bone mass in various animal models of osteoporosis and is currently being developed for preventive and curative treatment of postmenopausal osteoporosis. Iliac bone samples were obtained from 20 male monkeys: 4 untreated control animals, 12 animals sacrificed at the end of a 13-week treatment with high dose levels of S 12911 (750, 275, or 100 mg/kg/day orally), and 4 animals sacrificed 6 weeks after the end of a 13-week treatment with S 12911 (750 or 100 mg/kg/day orally). The distribution of Sr was determined and quantified by X-ray microanalysis. Changes at the crystal level were evaluated by X-ray diffraction and Raman microspectrometry. In the control animals, traces of Sr were found to be homogeneously distributed throughout the bone tissue. In the treated monkeys, Sr could only be detected in calcified matrix. In monkeys sacrificed at the end of the treatment, Sr was found to be dose-dependently incorporated into the mineral substance of the compact and cancellous bone. Sr was heterogeneously distributed with three to four times more Sr in new than in old compact bone, and approximately two and a half times more Sr in new than in old cancellous bone. The bone Sr content dramatically decreased in the animals sacrificed 6 weeks after the end of the treatment. Diffraction showed no significant changes in the characteristics of the crystal lattice. Sr appeared to be easily exchangeable from bone mineral and was slightly linked to mature crystals through ionic substitutions. Even at the highest dose level tested, less than 1 calcium ion out of 10 was substituted by 1 Sr ion in each crystal. In conclusion, taken up by bone, Sr was heterogeneously distributed with a higher concentration in new than in old bone but induced no major modifications of the bone mineral (crystallinity, crystal structure) at the crystal level. As a result, a treatment with S 12911 Sr salt should not induce any alteration of bone mineral.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8864905     DOI: 10.1002/jbmr.5650110915

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  46 in total

1.  The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years.

Authors:  E T Middleton; S A Steel; M Aye; S M Doherty
Journal:  Osteoporos Int       Date:  2011-01-28       Impact factor: 4.507

Review 2.  Is the calcium receptor a molecular target for the actions of strontium on bone?

Authors:  Edward M Brown
Journal:  Osteoporos Int       Date:  2003-03-12       Impact factor: 4.507

3.  Strontium ranelate for the treatment of osteoporosis.

Authors:  Ignac Fogelman; Glen M Blake
Journal:  BMJ       Date:  2005-06-18

4.  Bone-targeting parathyroid hormone conjugates outperform unmodified PTH in the anabolic treatment of osteoporosis in rats.

Authors:  Yang Yang; Ali Aghazadeh-Habashi; Arash Panahifar; Yuchin Wu; Krishna H Bhandari; Michael R Doschak
Journal:  Drug Deliv Transl Res       Date:  2017-08       Impact factor: 4.617

Review 5.  Prevention of vertebral fractures by strontium ranelate in postmenopausal women with osteoporosis.

Authors:  Juliet Compston
Journal:  Osteoporos Int       Date:  2005-01       Impact factor: 4.507

Review 6.  Strontium ranelate: a novel mode of action leading to renewed bone quality.

Authors:  Patrick Ammann
Journal:  Osteoporos Int       Date:  2005-01       Impact factor: 4.507

7.  Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies.

Authors:  J Y Reginster; P J Meunier
Journal:  Osteoporos Int       Date:  2003-03-12       Impact factor: 4.507

8.  Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis.

Authors:  P J Meunier; J Y Reginster
Journal:  Osteoporos Int       Date:  2003-03-12       Impact factor: 4.507

9.  Systemic treatment with strontium ranelate promotes tibial fracture healing in ovariectomized rats.

Authors:  Y F Li; E Luo; G Feng; S S Zhu; J H Li; J Hu
Journal:  Osteoporos Int       Date:  2009-12-03       Impact factor: 4.507

10.  The morphology and lattice structure of bone crystal after strontium treatment in goats.

Authors:  Zhaoyang Li; William W Lu; Lianfu Deng; Peter K Y Chiu; David Fang; Raymond W M Lam; John C Y Leong; Keith D K Luk
Journal:  J Bone Miner Metab       Date:  2009-07-15       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.